Vaccination-based targeting of endothelial cell function, demonstrated for GRIN2D in this paper, offers certain benefits over these other novel approaches to tumour targeting, not least its potential for a relative lack of cost, due to the persistence of the immune response, and the avoidance of regular drug infusions. Here, GRIN2D is linked to neoplasm.